Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries

NCT ID: NCT03859908

Last Updated: 2023-05-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-05
• Study Completion Date: 2021-01-27

Brief Summary

Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.

Detailed Description

Preoperative antiseptic Chlorhexidine based on alcohol has been established as gold standard of care for clean contaminated wounds. It was compared to Iodine solutions non-alcohol based. There is a question about alcohol based solution was a confounder in the comparison. The aim of this study is to compare the efficacy of both solutions alcohol based, 0.7% iodine povacrylex plus 74% alcohol, against gluconate chlorhexidine 2% plus 70% alcohol, in clean contaminated wounds, in major abdominal elective surgeries, in a wider range than colorectal surgeries, Materials and methods. With a pragmatic randomized, phase 4, controlled clinical trial. Comparison of two antiseptic solutions, using manufacturer (3M) sterile appliers' for both products, Food and Drugs Agency approved.

Quality of data will be assured by first training all surgeons and residents besides researchers in the study protocol for protocol compliance in subject identification, randomization moment, and follow up. There is a plan for weekly monitoring of protocol compliance, and monthly data monitoring and auditing from Faculty of Medicine Research Unit.

Monitoring and auditing will comply protocol compliance and data integrity against subject's medical records and random interviews of patients in their post-surgical control.

Surgical Site Infection definitions are those taken from Centers for Disease Control definitions.

Standard Operating Procedures will be established in all moments of the trial, from subject identification, informed consent, recruitment, randomization process in the operating room, and data collection in pre specified files for data collection and data management. Protocol compliance and Standard Operating Procedures compliance will be monitored by Principal Investigator constantly. Report of adverse events will be done in accordance to Salvadoran National ethics committee Standard Operating Procedures as also any other communication such as protocol deviance or amendments. Previous research has not reported adverse events, but we will be expectant to their appearance.

Sample size was calculated for a total of 964 subjects, 482 in each group, using statistics software, were we established a statistic significant level for a bilateral hypothesis of 95% and a power of 80%, based on previous research of comparison of both solutions to get a probability of SSI of 4.2% in Chlorhexidine group against 8.6% in Iodine povacrylex group.

We will establish a strict follow up of patients in the 30 days considered as post-operative time, by enabling the whole public health system to integrate in subjects´, surgical care (primary care) to diminish the probability of missing data.

Data analysis will be done following "intention to treat" analysis principle. Primary outcome will be any kind of Surgical Site Infection, categorical variable, will be analyzed with chi square for a bilateral hypothesis, and also measure the difference with risk ratio and its 95% confidence interval.

Conditions

Surgical Site Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Iodine-Povacrylex Alcohol

Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control

Group Type: EXPERIMENTAL

Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML

Intervention Type: DRUG

As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis

Chlorhexidine Alcohol

Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control

Group Type: ACTIVE_COMPARATOR

Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML

Intervention Type: DRUG

As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis

Interventions

Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML

As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis

Intervention Type: DRUG

Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML

As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis

Intervention Type: DRUG

Other Intervention Names

[DuraPrep]; SoluPrep; ChloraPrep

Eligibility Criteria

Inclusion Criteria

Elective surgery categorized as clean contaminated surgery Major abdominal

-

Exclusion Criteria

• American Society of Anesthesia III-IV
• Laparoscopic cholecystectomy
• Inguinal hernias classification I, II
• Obese subjects with Body Mass Index more than 35 or malnourished
• immunocompromised subjects
• neoplasia Preoperative hospital stay more than 7 days allergic to any of the solutions used in the trial

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universidad de El Salvador

OTHER

Sponsor Role: lead

Responsible Party

Maria-Virginia Rodriguez Funes

Clinical research coordinator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Maria-Virginia Rodriguez, MD, FACS

Role: PRINCIPAL_INVESTIGATOR

Universidad de El Salvador

Locations

Hospital Nacional Rosales

San Salvador, , El Salvador

Countries

El Salvador

Other Identifiers

CNEIS/2018/049

Identifier Type: OTHER

Identifier Source: secondary_id

Iodine alcohol Trial

Identifier Type: -

Identifier Source: org_study_id